MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, BMRN made $776,133K in revenue. -$30,744K in net income. Net profit margin of -3.96%.

Income Overview

Revenue
$776,133K
Net Income
-$30,744K
Net Profit Margin
-3.96%
EPS
-$0.16
Unit: Thousand (K) dollars
Revenue Breakdown
    • US
    • Europe
    • Rest Of World
    • Others
Revenue Breakdown
    • VOXZOGO
    • VIMIZIM
    • NAGLAZYME
    • Others

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Total revenues
776,133 825,410 745,145 747,313
Cost of sales
140,085 150,090 151,558 136,139
Research and development
409,478 161,308 158,731 173,509
Selling, general and administrative
268,415 232,279 206,116 266,607
Intangible asset amortization
4,847 4,846 4,847 9,651
Gain on sale of nonfinancial assets
0 0 0 0
Total operating expenses
822,825 548,523 521,252 585,906
Income (loss) from operations
-46,692 276,887 223,893 161,407
Interest income
17,854 18,827 19,013 17,680
Interest expense
2,579 2,679 2,863 3,062
Other income, net
5,093 4,833 -1,954 -6,871
Income (loss) before income taxes
-26,324 297,868 238,089 169,639
Provision for income taxes
4,420 57,336 52,403 44,696
Net income (loss)
-30,744 240,532 185,686 124,943
Earnings (loss) per share, basic (in dollars per share)
-0.16 1.25 0.97 0.66
Earnings (loss) per share, diluted (in dollars per share)
-0.16 1.23 0.95 0.65
Weighted average common shares outstanding, basic (in shares)
192,032,000 191,907,000 190,967,000 -379,382,000
Weighted average common shares outstanding, diluted (in shares)
192,032,000 197,091,000 196,474,000 -400,206,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Rest Of World$140,187K Latin America$97,618K Europe$195,184K US$274,114K Net income (loss)-$30,744K ALDURAZYME-Sales Channel ThroughIntermediary$53,709K Products ExcludingALDURAZYME-Sales Channel...$707,103K Provision for income taxes$4,420K Income (loss) beforeincome taxes-$26,324K Other income, net$5,093K Interest income$17,854K Royalty And Other$15,321K Product$760,812K Interest expense$2,579K Income (loss) fromoperations-$46,692K Total revenues$776,133K Total operatingexpenses$822,825K Intangible assetamortization$4,847K Selling, general andadministrative$268,415K Research and development$409,478K Cost of sales$140,085K

biomarin-logo-svg

BIOMARIN PHARMACEUTICAL INC (BMRN)

biomarin-logo-svg

BIOMARIN PHARMACEUTICAL INC (BMRN)